Hanson Wade Group’s Post

𝐁𝐫𝐚𝐢𝐧𝐒𝐭𝐨𝐫𝐦 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐥𝐢𝐠𝐧𝐬 𝐰𝐢𝐭𝐡 𝐅𝐃𝐀 𝐨𝐧 𝐂𝐌𝐂 𝐀𝐬𝐩𝐞𝐜𝐭𝐬 𝐟𝐨𝐫 𝐍𝐮𝐫𝐎𝐰𝐧® 𝐏𝐡𝐚𝐬𝐞 𝟑𝐛 𝐓𝐫𝐢𝐚𝐥 BrainStorm Cell Therapeutics (NASDAQ: BCLI) Brainstorm Cell Therapeutics has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b trial for NurOwn®, its investigational therapy for ALS. This follows the positive momentum from April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement, providing clarity on the trial's design and endpoints. "This in-person Type C meeting with the FDA was crucial as we finalize preparations for our pivotal Phase 3b trial of NurOwn. We are very pleased with the outcome and are now aligned on resolving all previously outstanding CMC questions," said Chaim Lebovits Chaim Lebovits, President & CEO of BrainStorm. "We are committed to working closely with the FDA and are excited to move forward with the Phase 3b trial to address the unmet needs of ALS patients." #ALS #StemCellTherapy #ClinicalTrials #FDA #NurOwn #BrainStormCellTherapeutics #Biotech #NeurodegenerativeDiseases

📢Novo Nordisk Acquires Cardior Pharmaceuticals for €1025bn: Promising Breakthrough in Heart Failure Treatment 📢 Novo Nordisk is acquiring Cardior Pharmaceuticals for up to €1.025bn, including milestone payments. ✨ Cardior's lead compound CDR132L is currently in Phase II clinical development for heart failure treatment. ⚙️ Cardior uses a non-coding RNA inhibitor to target microRNA-132, a central regulator of pathological cardiac remodelling processes. 💡 Novo Nordisk plans to initiate a Phase II trial for CDR132L in a chronic heart failure population. #BioprocessUpdates #NovoNordisk #CardiorPharmaceuticals #acquisition #clinicaldevelopment #heartfailure #CDR132L #PhaseIItrial #noncodingRNAinhibitor #microRNA132 #cardiacremodeling #chronicheartfailure #pharmaceuticalindustry #milestonepayments #healthcare #researchanddevelopment ▷ Read the full article here: 📎 https://lnkd.in/dti4Bd_6

𝐛𝐢𝐨𝐒𝐞𝐞𝐝𝐢𝐧 𝐍𝐄𝐖 𝐜𝐨𝐥𝐮𝐦𝐧, 𝐭𝐨 𝐬𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮 𝐭𝐡𝐞 𝐯𝐢𝐬𝐢𝐨𝐧 𝐚𝐧𝐝 𝐭𝐫𝐞𝐧𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐦𝐚𝐫𝐤𝐞𝐭. 𝐓𝐢𝐭𝐥𝐞 𝐟𝐨𝐫 𝐭𝐨𝐝𝐚𝐲’𝐬 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: bioSeedin bioSeedin Facilitates Strategic Licensing Partnership Between Supercede Therapeutics Supercede Therapeutics, Inc. and Leading Research Institutions bioSeedin is proud to announce its pivotal role in brokering a strategic cross-border licensing deal between Supercede Therapeutics and premier research institutions with a total deal value of $100M USD. This landmark agreement marks a significant step in the development of innovative treatments for obesity, focusing on a unique mechanism that simultaneously increases lean muscle mass while reducing fat. For full article, please see the link: https://lnkd.in/grA983tw

🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

The evolution of biologics 🧪 has been a game-changer for those who live with multiple sclerosis, offering hope and improved quality of life. In our latest blog post, we explore 🌎 how biologics work to treat MS and the different biologics available to MS patients.

https://lnkd.in/gaAKgDzW Key Insights: • As per the agreements, FUJIFILM Cellular Dynamics stands to gain specific development and regulatory milestone payments, along with royalties tied to products developed under the collaboration between the companies Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #fujifilm #autoimmune #inflammatory #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Ready to revolutionise the storage of mRNA drugs 🤓

Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec

What's the state of the commercial R&D #antibodydrugconjugates space? The Antibody Society has just released its summary of the commercial antibody therapeutics pipeline that they carefully manually curate. Having reviewed it I've summarised over 400 ADCs and RITs that have been or are in commercial R&D up to Oct 2023. Key insight: It's a competitive space, around relatively few targets with a substantial risk of termination. It's exciting and competitive times for those of us driving #antibodydrugconjugates #scienceandtechnology #innovation #precisionmedicine #pharmacology to help transform patients' lives. The first three rows in the table correspond to the graphs in descending order.

The hotly anticipated 2nd RNA Assay Development & Screening Summit returns to Boston, August 20-22, 2024, to revolutionize RNA-targeted drug discovery with robust assays and screens. Check out the Brand-New Event Guide here: https://ter.li/zuknlg Don’t miss your opportunity to see expert talks with industry leaders from AstraZeneca, Arrakis Therapeutics, Biogen, NextRNA Therapeutics, Accent Therapeutics, Inc. , Atavistik Bio and many more, at the industry's first and only conference dedicated to supporting in-house assay development and screening strategies for discovering selective RNA-targeting small molecules. #RNAtargeting #RNA #smallmolecules #drugdiscovery #assaydevelopment #assay #screening